萨瑞普塔治疗

最新新闻

• 评级变动
  Analysts' Opinions Are Mixed on These Healthcare Stocks: Vericel (VCEL), Sarepta Therapeutics (SRPT) and Neumora Therapeutics, Inc. (NMRA)
  TipRanks · 2026/7/28
• 评级变动
  A Quick Look at Today's Ratings for Sarepta Therapeutics(SRPT.US), With a Forecast Between $5 to $38
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• Wedbush Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $35
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• 评级变动
  Mizuho Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $31
  \u5e02\u573a\u8d44\u8baf · 2026/7/10
• 评级变动
  J.P. Morgan Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Raises Target Price to $23
  \u5e02\u573a\u8d44\u8baf · 2026/9/2
• J.P. Morgan Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Announces Target Price $20
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• 评级变动
  RBC Capital Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Cuts Target Price to $19
  \u5e02\u573a\u8d44\u8baf · 2026/6/18
• 评级变动
  Evercore Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Raises Target Price to $19
  \u5e02\u573a\u8d44\u8baf · 2026/5/15
• 评级变动
  Morgan Stanley Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Maintains Target Price $25
  \u5e02\u573a\u8d44\u8baf · 2026/7/27
• Citi Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating, Maintains Target Price $13
  \u5e02\u573a\u8d44\u8baf · 2026/9/28
• 评级变动
  Needham Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/28
• 评级变动
  J.P. Morgan Remains a Hold on Sarepta Therapeutics (SRPT)
  TipRanks · 2026/9/2
• 评级变动
  Evercore Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Maintains Target Price $19
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• William Blair Initiates Sarepta Therapeutics(SRPT.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/29
• 评级变动
  Barclays Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Maintains Target Price $20
  \u5e02\u573a\u8d44\u8baf · 2026/8/8
• 评级变动
  Wolfe Research Upgrades Sarepta Therapeutics(SRPT.US) to Buy Rating, Announces Target Price $27
  \u5e02\u573a\u8d44\u8baf · 2026/7/9
• 评级变动
  H.C. Wainwright Reaffirms Their Sell Rating on Sarepta Therapeutics (SRPT)
  TipRanks · 2026/5/7
• 评级变动
  J.P. Morgan Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/15
• 评级变动
  J.P. Morgan Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Announces Target Price $19
  \u5e02\u573a\u8d44\u8baf · 2026/5/19
• H.C. Wainwright Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating, Maintains Target Price $5
  \u5e02\u573a\u8d44\u8baf · 2026/10/5

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。